<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'>
<creators>
<creator>
<creatorName>Agaeva, G..</creatorName>
<affiliation>Частная клиника Гранд Госпиталь, Azerbaijan</affiliation>
</creator>
<creator>
<creatorName>Ghidaiatov, A.</creatorName>
<affiliation>Azerbaijan Medical University, Baku, Azerbaijan</affiliation>
</creator>
</creators>
<titles>
<title xml:lang='ru'>Гепатит Dельта: современное состояние проблемы(литературный обзор)</title>
</titles>
<publisher>Instrumentul Bibliometric National</publisher>
<publicationYear>2017</publicationYear>
<relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>1729-8687</relatedIdentifier>
<subjects>
<subject>hepatitis delta virus</subject>
<subject>HDV infection</subject>
<subject>HDV
treatment</subject>
<subject schemeURI='http://udcdata.info/' subjectScheme='UDC'>616.36–002</subject>
</subjects>
<dates>
<date dateType='Issued'>2017-12-31</date>
</dates>
<resourceType resourceTypeGeneral='Text'>Journal article</resourceType>
<descriptions>
<description xml:lang='en' descriptionType='Abstract'><p><em>Hepatitis Delta is the most severe form of viral hepatitis in humans. The hepatitis Delta virus (HDV) is a defective RNA virus, which requires the hepatitis B virus (HBV) surface antigen (HBsAg) for complete replication and transmission. Several studies have shown that chronic HDV infection leads to more severe liver diseases than chronic HBV mono-infection, with an accelerated course of fibrosis progression, possibility of a slightly increased risk of hepatocellular carcinoma development and early decompensation in the setting of established cirrhosis. Only interferon-alfa treatment has been shown to exert some antiviral activity against HDV and has been linked to improve the clinical long-term outcome. Data on the use of PEGylated interferon (PEG-IFN) confirm earlier findings, leading to prolonged virological off-treatment responses in about one quarter of patients, but long-term HDV RNA relapses may occur. HBsAg clearance should be the preferred endpoint of interferon-based therapies of HDV. Alternative treatment options including HBV entry inhibitors and prenylation inhibitors are currently in early clinical development.</em></p></description>
</descriptions>
<formats>
<format>application/pdf</format>
</formats>
</resource>